SLRX Salarius Pharmaceuticals, Inc.

Nasdaq salariuspharma.com


$ 4.01 $ 0.00 (0 %)    

Tuesday, 14-Oct-2025 07:23:10 EDT
QQQ $ 594.96 $ 0.00 (0 %)
DIA $ 458.08 $ 0.00 (0 %)
SPY $ 657.22 $ 0.00 (0 %)
TLT $ 91.06 $ 0.00 (0 %)
GLD $ 380.09 $ 0.00 (0 %)
$ 3.96
$ 4.01
$ 3.86 x 3,011
$ 4.00 x 18
-- - --
$ 3.64 - $ 108.00
527,819
na
2.02M
$ 1.00
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-12-2025 06-30-2025 10-Q
2 05-14-2025 03-31-2025 10-Q
3 03-21-2025 12-31-2024 10-K
4 11-14-2024 09-30-2024 10-Q
5 08-09-2024 06-30-2024 10-Q
6 05-13-2024 03-31-2024 10-Q
7 03-22-2024 12-31-2023 10-K
8 11-09-2023 09-30-2023 10-Q
9 08-10-2023 06-30-2023 10-Q
10 05-11-2023 03-31-2023 10-Q
11 03-27-2023 12-31-2022 10-K
12 11-10-2022 09-30-2022 10-Q
13 08-05-2022 06-30-2022 10-Q
14 05-12-2022 03-31-2022 10-Q
15 03-25-2022 12-31-2021 10-K
16 11-04-2021 09-30-2021 10-Q
17 08-05-2021 06-30-2021 10-Q
18 05-12-2021 03-31-2021 10-Q
19 03-18-2021 12-31-2020 10-K
20 11-12-2020 09-30-2020 10-Q
21 08-12-2020 06-30-2020 10-Q
22 05-14-2020 03-31-2020 10-Q
23 03-23-2020 12-31-2019 10-K
24 11-12-2019 09-30-2019 10-Q
25 07-17-2019 06-30-2019 10-Q
26 05-01-2019 03-31-2019 10-Q
27 03-06-2019 12-31-2018 10-K
28 11-05-2018 09-30-2018 10-Q
29 08-01-2018 06-30-2018 10-Q
30 05-02-2018 03-31-2018 10-Q
31 03-07-2018 12-31-2017 10-K
32 11-06-2017 09-30-2017 10-Q
33 08-02-2017 06-30-2017 10-Q
34 05-03-2017 03-31-2017 10-Q
35 03-08-2017 12-31-2016 10-K
36 11-02-2016 09-30-2016 10-Q
37 08-03-2016 06-30-2016 10-Q
38 05-04-2016 03-31-2016 10-Q
39 03-08-2016 12-31-2015 10-K
40 11-04-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 salarius-pharmaceuticals-amends-merger-terms-with-decoy-to-set-1050-baseline-conversion-price-375-floor-price-for-preferred-stock

As previously disclosed, Salarius Pharmaceuticals, Inc. (the "Company") entered into an Agreement and Plan of Merger da...

 reported-earlier-salarius-pharmaceuticals-granted-nasdaq-extension-to-regain-compliance-with-equity-and-minimum-bid-price-requirements-by-august-2025

On July 28, 2025, Salarius Pharmaceuticals, Inc. ("Salarius") received notification from The Nasdaq Stock Market LLC (&...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION